New member of the company

news, ,

We are happy to announce that Gergely Tóth will join the team of CarboHyde as a Strategic Director, responsible for the company’s financial, legal, and other functional areas.
Gergely has 2+ years of experience in the pharma sector; prior to that, he had worked in various roles in the energy industry.

“I Think This Is The Beginning Of A Beautiful Friendship!
I’m very excited to join a great Pharmaceutical startup, CarboHyde, as a Director of Strategy. I will be responsible for the financial, legal, and other functional areas. Here, we develop carbohydrate-based therapies and will help others to do so. Moreover, we are committed to building a TEAL-based company culture, which we believe will be a key strength of our company.”

Welcome on board, Gergely!

New member of the Scientific Advisory Board

news,

We are proud to share the next member in the CarboHyde family, joining our excellent experts on the Advisory Board. Ákos Lőrincz has a complementary experience in physiology and immunology; we all respect and need to advance our pipeline most efficiently. 

Ákos is an Assistant Professor at Semmelweis University, Institute of Physiology, and a practicing cardiologist. His scientific interest is the biology of extracellular vesicles, particularly the formation of immune cell-derived extracellular vesicles and their role in immune communication. He is also convinced that the general goal of basic research is to acquire knowledge that can be applied in clinical work; therefore, he is intensively studying these vesicles’ diagnostic and therapeutic potential.

Related to carbohydrates, the surface of cellular and subcellular biological structures (e.g., extracellular vesicles) is covered with carbohydrates. The role of the glycocalyx in the formation and addressing of vesicles has already been demonstrated. In his research, He is looking for the answer to whether media with different carbohydrate compositions can increase the stability of storage-sensitive vesicle structures.

Welcome on board, Ákos!

New pipeline asset

news,

CarboHyde announces the development of a new pipeline asset in an undisclosed partnership: we will work on the optimization, scale-up, and industrialization of a novel, carbohydrate-based non-viral gene delivery system which provided promising results in proof-of-concept preclinical studies. We expect the technology to be widely compatible with different oligonucleotides and become a safer alternative to currently used LNPs.

International cyclodextrin Symposium

news,

The cyclodextrin event of the year is around the corner with world-class speakers from all around the globe delivering talks on all kinds of topics related to our favorite sugars.

Tamas Sohajda from our advisory board talks about cyclodextrins as antiviral agents and drug delivery systems.

We hope to see many new faces there too!

Check out the schedule here: https://www.ismn.cnr.it/ics20/pdf/ICS_program_rev.2022_5_7.pdf

New member of the Scientific Advisory Board

news

We are happy to announce an expansion of the CarboHyde family. We have invited several world-renowned scientists and experts from different countries and institutions to our Scientific Advisory Board, who can help us in our challenging journey of developing carbohydrate-based therapeutic nutrition agents. We will introduce them one by one in the coming weeks.

Tamas Sohajda has a long professional history in the field of cyclodextrins – he was the head of R&D and CEO of CycloLab for 5+ years – widely experienced in chemistry, analysis, formulation, etc., regulatory affairs, industrialization, and therapeutic applications. We are honored that he accepted our invitation to support us through our upcoming preclinical and clinical development obstacles, feed us new ideas and improve existing ones.

Welcome on board, Tamas!

CLN3 is required for the clearance of glycerophosphodiesters from lysosomes

drug development,

A new study shows CLN3, a lysosomal transmembrane protein, is required for the lysosomal clearance of glycerophospholipid and that glycerophosphoinositol is a disease biomarker for Batten disease. Great work to advance lysosomal storage disorder treatments from a team from Stanford University, The National Institutes of Health, Leibniz Institute on Aging – Fritz Lipmann Institute (FLI), Ludwig-Maximilians-Universität München, Whitehead Institute for Biomedical Research, University of Virginia School of Medicine and David Sabatini!

Full article on nature.com

carbohyde blog, rare disease